Atenor SA (ATEB)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 0.994 |
|---|---|
| 52-week range | 0.986 – 3.060 |
| Return, 1 month / 3 months | +0.0% / −36.3% |
| Return, 1 year / 3 years | −65.8% / −86.9% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 40.9% |
| Worst drawdown (1 year) | -67.5% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Atenor is a Belgian property developer based in Brussels that creates large urban development projects, chiefly office buildings, often on former industrial or brownfield land. It works with investors, companies and public bodies as customers and partners, and it develops projects in Belgium and in several other European countries. Its work covers the design, planning and delivery of mixed urban districts and commercial buildings, from site acquisition through construction and letting.
The shares are listed on the Euronext Brussels in Belgium under the code ATEB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Atenor SA (ATEB) trades on the Euronext Brussels in Belgium. It last closed at EUR 0.994 on 22 October 2026.
Its price-based Market X-Ray is 14 out of 100 (a weak price profile), ranking 103 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 65.8% and over the last three months it fell 36.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 7 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -43.8% | ||
| From 52-week high | -67.4% | ||
| Momentum | 6 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -36.3% | ||
| 6-month return | -46.4% | ||
| 12-month return, skipping the last month | -65.8% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -67.5% | ||
| Liquidity | 34 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.1% |
|---|---|
| 1 month | +0.0% |
| 3 months | −36.3% |
| 6 months | −46.4% |
| 1 year | −65.8% |
| 3 years | −86.9% |
| 5 years | −96.8% |
Signals
| 50-day / 200-day average | 1.112 / 1.768 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.027 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 May 2023 | EUR 1.8690 |
| 26 Apr 2022 | EUR 1.7780 |
| 26 Apr 2021 | EUR 1.6940 |
| 27 Apr 2020 | EUR 1.6170 |
| 29 Apr 2019 | EUR 1.5400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.